Trials / Completed
CompletedNCT00336986
Efficacy Study of IL-21 to Treat Metastatic Melanoma
An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant interleukin-21 |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-06-15
- Last updated
- 2023-08-14
Locations
7 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00336986. Inclusion in this directory is not an endorsement.